News

Intercytex looks ahead to BLA for its lead wound product

The UK regenerative medicine company, Intercytex Group Plc, is moving forward with a pivotal Phase 3 trial of its lead product for chronic wounds and anticipates filing a biologic licence application for the product with the US Food and Drug Administration in the second half of 2009.

New class of antibiotics may subdue MRSA

Research published in the journal, Science, and financially supported by the Wellcome Trust, describes how a new class of antibiotics could be developed to treat multi-drug resistant Staphylococcus aureus (MRSA).

Alizyme to receive $3 million milestone from Takeda

Takeda Pharmaceutical Company Ltd has decided to start a Phase 3 study in Japan of a new gastrointestinal lipase inhibitor for obesity, cetilistat, which will trigger a $3 million payment to the compound’s developer, Alizyme Plc.

Privately-owned Cellzome in $1.6 billion alliance with GSK

A privately-owned US drug discovery company with operations in Cambridge, UK and Heidelberg, Germany has entered into a strategic alliance with GlaxoSmithKline to discover and develop kinase-targeted therapeutics to treat inflammatory diseases.

New biopharmaceutical company created in Switzerland

A new biopharmaceutical company has been created in Switzerland to focus on the development of anti-infectives for women’s health. The company, Lumavita AG, is based in Basle, and is being supported by Atlas Venture, BB Biotech Ventures and BioMedInvest. On 2 September 2008, it announced the successful closing of a Series A financing for €11 million.